Long-Term Persistence of Antibody Response with Two Doses of Inactivated Hepatitis A Vaccine in Children
Open Access
- 24 July 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Infectious Diseases and Therapy
- Vol. 9 (4), 785-796
- https://doi.org/10.1007/s40121-020-00311-8
Abstract
Introduction Hepatitis A virus infection is more severe in adults than children. Although vaccination can protect adults, current childhood programs cover a large population more successfully. Childhood vaccination is, therefore, a solution to protecting adults if it induces lasting immunity. Fifteen-year protection has been demonstrated in children, but longer-term data are only available for adults. We aimed to predict long term persistence of antibody in children beyond 15 years and assess if immunological mechanisms triggered by vaccination support longer-term protection. Methods Long-term clinical studies using hepatitis A (HAV) or A/B vaccines (HAB) containing 720 or 1440 Enzyme-linked immunosorbent assay Units (EU) of hepatitis A virus antigen were identified. Duration of persistence of antibodies and possible protection was determined by descriptively comparing antibody geometric mean concentration (GMC) kinetics, as well as GMC (95% confidence interval) at 15 years post-vaccination across studies. Immunological mechanism studies describing hepatitis A vaccination were identified. Results One study in children 12–15 years (2-dose HAB 720) and four in adults (2-dose HAV 1440 and 3-dose HAB 720) showed comparable GMC kinetics and per year rates of change up to 15 years. At 15 years, the GMC in children [414.7 mEU/ml (336.9; 510.5)] was in the same range as in adults [range 282.6 (217.6; 367.0) to 550.1 (416.0; 727.4)]. Based on these data, mathematical model predictions from adult studies (showing > 85% protected at 50 years) were deemed likely to also apply to children. Studies identified, both humoral and cell-mediated responses are induced following vaccination. Conclusion Based on comparable antibody data in adults and children up to 15 years, similar longer-term antibody persistence is expected in children with 2-dose inactivated hepatitis A 720 containing vaccine at least up to 50 years. Accordingly, improving routine childhood hepatitis A vaccination coverage could protect against more severe disease in adulthood. Plain language summary Trial Registration ClinicalTrials.gov identifiers, NCT00875485, NCT01000324, NCT01037114, NCT00289757, NCT00291876.Funding Information
- GlaxoSmithKline
This publication has 23 references indexed in Scilit:
- Long-term antibody persistence after vaccination with a 2-dose Havrix™ (inactivated hepatitis A vaccine): 20 years of observed data, and long-term model-based predictionsVaccine, 2015
- Model based estimates of long-term persistence of inactivated hepatitis A vaccine-induced antibodies in adultsVaccine, 2014
- Seventeen-year antibody persistence in adults primed with two doses of an inactivated hepatitis A vaccineHuman Vaccines & Immunotherapeutics, 2012
- LONG-TERM IMMUNITY AFTER TWO DOSES OF INACTIVATED HEPATITIS A VACCINE, IN ARGENTINEAN CHILDRENThe Pediatric Infectious Disease Journal, 2010
- Correlation between humoral and cellular immune responses and the expression of the hepatitis A receptor HAVcr-1 on T cells after hepatitis A re-vaccination in high and low-responder vaccineesVaccine, 2009
- Cell mediated and antibody immune response to inactivated hepatitis A vaccineVaccine, 2005
- Incidence of Hepatitis A in Israel Following Universal Immunization of ToddlersJAMA, 2005
- A review of the efficacy, immunogenicity and tolerability of a combined hepatitis A and B vaccineExpert Review of Vaccines, 2004
- Production of Interferon-γ and Interleukin-10 After Inactivated Hepatitis A ImmunizationPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2003
- Single dose inactivated hepatitis A vaccine: Rationale and clinical assessment of the safety and immunogenicityJournal of Medical Virology, 1994